Welcome to our dedicated page for Globus Med SEC filings (Ticker: GMED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Globus Medical filings document formal disclosures for a medical device company focused on musculoskeletal solutions and enabling technologies. Recent Form 8-K reports furnish quarterly and annual operating results, preliminary sales information, financial guidance and related press releases covering net sales, earnings measures, cash flow and segment commentary.
The company’s proxy materials cover board elections, governance practices, executive compensation, equity awards and annual meeting matters. Other current reports document leadership transitions, director departures and related governance events, tying the filing record to Globus Medical’s operating performance, management structure and public-company reporting obligations.
Keith W. Pfeil, identified as President, CEO and a director of Globus Medical (GMED), received a grant of 40,000 stock options on 07/18/2025 with an exercise price of $56.34. The options are exercisable into 40,000 shares of Class A common stock and are held directly. Vesting begins on 07/18/2025 and occurs over four years: one-fourth vests on 07/18/2026 and the remainder vests ratably monthly over the following 36 months. The form reports the grant as an acquisition (A) of derivative securities (stock options).
Kyle Kline, Senior Vice President and Chief Financial Officer of Globus Medical (GMED), received an award of stock options on 07/18/2025. The grant totals 20,909 stock options to purchase Class A common stock at an exercise price of $56.34 per share. The options vest over four years with one-quarter vesting on the first anniversary of the vesting commencement date (07/18/2026) and the remainder vesting ratably each month over the following 36 months. The options expire on 07/18/2035 and are reported as directly beneficially owned following the transaction.
Kyle Kline, identified as Senior Vice President, Chief Financial Officer, filed an initial Form 3 reporting derivative holdings in Globus Medical, Inc. (GMED) related to stock options. The report, for an event dated 07/18/2025, lists seven option grants exercisable on dates from 01/25/2031 through 01/30/2035 covering a total of 51,591 underlying shares of Class A common stock. Strike prices on the grants range from $51.87 to $93.12, and each grant is reported as held directly. No non-derivative (direct) shares of common stock are reported on Table I. The filing is signed by an attorney-in-fact on behalf of the reporting person.